Patents Issued in January 18, 2024
  • Publication number: 20240016923
    Abstract: Disclosed are modified hepatitis C virus (HCV) E1E2 glycoproteins. Disclosed are Disclosed are modified HCV E1E2 glycoproteins comprising a HCV E1 polypeptide; a first scaffold element; a HCV E2 polypeptide; and a second scaffold element, wherein the HCV E1 polypeptide does not comprise a transmembrane domain, and wherein the HCV E2 polypeptide does not comprise a transmembrane domain.
    Type: Application
    Filed: November 12, 2021
    Publication date: January 18, 2024
    Inventors: Brian G. Pierce, Thomas R. Fuerst, Eric A. Toth, Johnathan D. Guest, Steven K.H. Foung, Zhen-Yong Keck
  • Publication number: 20240016924
    Abstract: The present invention relates to the field of adjuvant and vaccination. In the present study, the inventors investigate whether P1, in addition to being an antigen, could act as an adjuvant by first exploring its capacity to stimulate epithelial TSLP production. They evaluated additional immunomodulatory effects of P1 on human nasal mucosal models, including cytokines and chemokines production, intracellular signaling pathways, mucosal DC activation, T cell proliferation, and antigen-specific B cell responses against a model antigen in vitro. Altogether, they reported the immunological mechanism underlying P1-vaccine and the interest of P1 as a nasal mucosal adjuvant. Thus, the present invention relates to an immunoadjuvant composition comprising the P1 peptide of the HIV-1 envelope subunit gp41.
    Type: Application
    Filed: December 3, 2021
    Publication date: January 18, 2024
    Inventors: Morgane BOMSEL, Daniela TUDOR
  • Publication number: 20240016925
    Abstract: There is provided a novel vaccine adjuvant, and more specifically, a vaccine adjuvant for stimulating a T lymphocyte-specific immune response, which includes an IL-12 protein and an IL-21 protein as active ingredients, or includes the polynucleotide encoding an IL-12 protein and the polynucleotide encoding an IL-21 protein as active ingredients.
    Type: Application
    Filed: August 4, 2023
    Publication date: January 18, 2024
    Applicant: SL VAXIGEN, INC.
    Inventors: Yong Bok SEO, Youngwoo CHOI, Sang Hee SIM
  • Publication number: 20240016926
    Abstract: Isolated monoclonal antibodies that bind to human complement component C6 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic methods for using the antibodies.
    Type: Application
    Filed: February 14, 2023
    Publication date: January 18, 2024
    Inventors: Frank Baas, Marc A. Van Dijk
  • Publication number: 20240016927
    Abstract: Provided herein are methods for making targeted therapeutics. In several embodiments, the therapeutics are directed against soluble agents such as toxins, venoms, and/or other factors that alter physiological biopathways as well as methods of using such therapeutics to treat patients or patient populations to reduce, eliminate, or inactivate, detrimental soluble agents that such patients or patient populations have been exposed to. In several embodiments, the therapeutics are directed to patient-specific disease markers. In several embodiments, the methods comprise screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent.
    Type: Application
    Filed: April 24, 2023
    Publication date: January 18, 2024
    Inventors: Richard B. Williams, Robert Guerrero
  • Publication number: 20240016928
    Abstract: Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGF?1 in the treatment of disease that involve TGF?1 dysregulation.
    Type: Application
    Filed: August 1, 2023
    Publication date: January 18, 2024
    Inventors: Thomas Schurpf, Abhishek Datta, Gregory J. Carven, Constance Martin, Ashish Kalra, Kimberly Long, Alan Buckler
  • Publication number: 20240016929
    Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 18, 2024
    Inventors: Emma S. COHEN, David C. LOWE, Robin BUTLER, Ian C. SCOTT, Katherine A. VOUSDEN, Martin D. STRAIN, Sara CARMEN, Elizabeth H. ENGLAND, Benjamin P. KEMP, David G. REES, Catherine L. OVERED-SAYER, Tomas M. MUSTELIN, Matthew SLEEMAN, Kirsty HOUSLAY
  • Publication number: 20240016930
    Abstract: A method for treating a patient comprising: (a) providing a composition comprising a population of T cells expressing both a chimeric antigen receptor (CAR) and a T cell receptor specific for a cytomegalovirus (CMV) antigen; (b) administering the composition to the patient; and (c) administering to the patient a viral vector encoding: (i) CMV pp65 and (ii) a fusion protein comprising exon 4 of CMV protein IE1 (e4) and exon 5 of CMV protein IE2 (e5) either prior to or subsequent to administering the composition comprising a population of T cells to the patient is described.
    Type: Application
    Filed: July 19, 2023
    Publication date: January 18, 2024
    Inventors: Don J. Diamond, Xiuli Wang
  • Publication number: 20240016931
    Abstract: Provided are a pharmaceutical composition comprising an anti-TSLP antibody and the use thereof. The pharmaceutical composition comprises an anti-TSLP antibody and a buffer.
    Type: Application
    Filed: November 22, 2021
    Publication date: January 18, 2024
    Inventors: Zhiwan WANG, Tingting WU, Xun LIU
  • Publication number: 20240016932
    Abstract: An object of the present invention is to provide a novel chimeric antigen receptor. The object can be achieved by a chimeric antigen receptor, comprising an antigen-binding domain, a transmembrane domain, and an intracellular signal domain containing a CD79A intracellular domain and a CD40 intracellular domain, wherein (A) the number of constituent amino acid residues between the antigen-binding domain and the transmembrane domain is 100 or less and/or (B) a target antigen of the antigen-binding domain is an antigen other than CD19.
    Type: Application
    Filed: November 9, 2021
    Publication date: January 18, 2024
    Applicant: National University Corporation Tokai National Higher Education and Research System
    Inventors: Seitaro TERAKURA, Jakrawadee JULAMANEE, Hitoshi KIYOI
  • Publication number: 20240016933
    Abstract: The present disclosure provides methods of anchoring active molecules on the surface of a cell, methods of anchoring at least two active molecules on the surface of a cell, and methods of enhancing an immune response to a target cell in a human.
    Type: Application
    Filed: November 5, 2021
    Publication date: January 18, 2024
    Inventors: James T. Kurnick, Ian Seymour Dunn, Matthew M. Lawler
  • Publication number: 20240016934
    Abstract: Compositions and methods for reducing MHC class II protein expression in a cell comprising genetically modifying CIITA for use e.g., in adoptive cell transfer therapies.
    Type: Application
    Filed: June 9, 2023
    Publication date: January 18, 2024
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Srijani Sridhar, Yong Zhang, William Frederick Harrington, Surbhi Goel
  • Publication number: 20240016935
    Abstract: A genetically modified cell includes (i) an exogenous oligomeric polypeptide having a variable region and a constant region, and (ii) exogenous CD8 ?-chain and ?-chain polypeptides.
    Type: Application
    Filed: September 27, 2023
    Publication date: January 18, 2024
    Inventors: Tatsuya MATSUNO, Masahiro OKANOJO, Ryosuke TAKAHASHI, Tetsuya NAKATSURA, Toshihiro SUZUKI
  • Publication number: 20240016936
    Abstract: Provided herein are uses of chimeric antigen receptors (CARs) for treating a cancer (such as B cell related cancer, e.g., multiple myeloma).
    Type: Application
    Filed: December 3, 2021
    Publication date: January 18, 2024
    Applicant: Celgene Corporation
    Inventors: Ethan Greene THOMPSON, Shari m. KAISER, Nathan Thomas MARTIN
  • Publication number: 20240016937
    Abstract: The present invention provides a composition containing a nucleic acid molecule and a buffer, and having the features of (a) being in the form of a solution at ambient temperature; and (b) a content of the nucleic acid molecule after storage at 25° C., relative humidity 60% for 4 weeks, of not less than 80% relative to the content at the time of start of the storage.
    Type: Application
    Filed: August 30, 2023
    Publication date: January 18, 2024
    Applicant: TORAY INDUSTRIES, INC.
    Inventors: Taimu YAMADA, Hidekazu TOYOFUKU
  • Publication number: 20240016938
    Abstract: Provided are methods for increasing the bioavailability of nucleoside medicinal agents in treating mitochondrial depletion syndromes. In particular, the methods relate to increasing the bioavailability of deoxycytidine and deoxythymidine by administering a therapeutically effective amount of deoxycytidine and deoxythymidine with food.
    Type: Application
    Filed: July 12, 2023
    Publication date: January 18, 2024
    Inventor: Aravind MITTUR
  • Publication number: 20240016939
    Abstract: The present invention relates generally to a liquid composition comprising cereal beta-glucan or a cereal extract comprising beta-glucan and an added inorganic and/or organic salt. Particularly, the present invention relates to a method for producing a liquid cereal beta-glucan comprising composition with retarded gelation and a method for transforming said gelled cereal beta-glucan comprising composition. Additionally, the present invention relates to said beta-glucan comprising composition as a food, food supplement, cosmetic, pharmaceutical or veterinary preparation. More particularly, the present invention pertains to a food, food supplement, cosmetic, pharmaceutical or veterinary preparation comprising said ?-cereal comprising composition. Finally, the present invention relates to the use of certain inorganic and/or organic salts for retarding gelation of a cereal beta-glucan comprising composition.
    Type: Application
    Filed: November 17, 2020
    Publication date: January 18, 2024
    Inventors: Mickaël Larnicol, Léa Schmidt, Marielle Le Maire
  • Publication number: 20240016940
    Abstract: Described herein are novel compositions comprising lipid-poly(ethylene glycol) (lipid-PEG) molecules or lipid-PEG like molecules, and methods of use thereof, e.g., for sustained delivery of therapeutic agents such as nucleic acids, proteins, and small molecules.
    Type: Application
    Filed: November 24, 2021
    Publication date: January 18, 2024
    Inventors: Jinjun Shi, Yuling Xiao
  • Publication number: 20240016941
    Abstract: The invention provides a combinations and pharmaceutical compositions comprising (i) a compound which is an indane according to Formula (I) or a pharmaceutically acceptable salt thereof; and (ii) one or more CFTR modulator; wherein R1, R2, R3, R4, n, Lk, (A), G and m are as defined herein. Also provided are therapeutic uses of such combinations and compositions in the treatment of conditions such as cystic fibrosis.
    Type: Application
    Filed: March 23, 2021
    Publication date: January 18, 2024
    Applicant: Antabio SAS
    Inventors: Martin Everett, Simon Leiris, David Thomas Davies, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
  • Publication number: 20240016942
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: March 17, 2021
    Publication date: January 18, 2024
    Inventors: Nan JI, Bin YANG, Xiaozhang ZHENG, Xiao ZHU
  • Publication number: 20240016943
    Abstract: In aspects, the invention provides a polypeptide construct comprising (a) a first polypeptide comprising an amino acid sequence derived from a basic helix of a transcription factor protein that comprises a basic helix-loop-helix domain; and (b) a second polypeptide comprising an amino acid sequence derived from a helix that extends in the C-terminal direction from the end of the loop of a basic helix-loop-helix domain of a transcription factor protein that comprises a basic helix-loop-helix domain; wherein the first polypeptide and the second polypeptide are linked through an interpolypeptide covalent linkage. Additional aspects of the invention are as described herein.
    Type: Application
    Filed: November 24, 2021
    Publication date: January 18, 2024
    Applicant: The University of Chicago
    Inventors: Raymond E. MOELLERING, Thomas E. Speltz, Sean SHANGGUAN
  • Publication number: 20240016944
    Abstract: The present disclosure is directed to pharmaceutical and diagnostic compositions comprising macropinocytosis selective non-binding protein-drug conjugates. These non-binding protein-drug conjugates comprise a non-binding fibronectin type III (FN3) domain coupled to a pharmaceutically active moiety or a diagnostic moiety. The disclosure is also directed to methods of treatment and diagnosis that involve administering the pharmaceutical compositions described herein to a subject in need.
    Type: Application
    Filed: November 10, 2021
    Publication date: January 18, 2024
    Inventors: Craig RAMIREZ, Andrew HAUSER, Nathan BEALS, Dafna BAR-SAGI, Akiko KOIDE, Shohei KOIDE
  • Publication number: 20240016945
    Abstract: Antibiotic agents conjugated to a guanidinium-rich molecular transporter (GR-MoTr) are provided. The drug conjugates show surprising increases in efficacy compared to the unconjugated drug in difficult-to-treat bacterial infections including biofilms, stationary and persister cells, and multi-drug resistant bacteria, as well as intracellular bacteria.
    Type: Application
    Filed: February 21, 2019
    Publication date: January 18, 2024
    Inventors: Melanie Huttner, Paul Wender, Lynette Cegelski, Xiaoyu ZANG, Alexandra Antonopolis
  • Publication number: 20240016946
    Abstract: A drug-loaded macromolecule and a preparation method therefor, the macromolecule specifically being a dentritic polymer loaded with a drug and a pharmacokinetic modifier, and relating in particular to connecting the drug to the dentritic polymer by means of a specific linker. The present macromolecule can be used to regulate the release speed of the drug, specifically by means of the selection of linker.
    Type: Application
    Filed: August 25, 2021
    Publication date: January 18, 2024
    Inventors: Jian HUANG, Lingjian ZHU, Zhongjun GUAN, Shaonan LIANG, Wenming REN, Cheng LIAO
  • Publication number: 20240016947
    Abstract: An antibody conjugating peptide including an amino acid having a photoreactive functional group, a physiologically active substance modified with the conjugating peptide, and an antibody conjugate having an antibody linked to the physiologically active substance are disclosed. When the physiologically active substance modified with the conjugating peptide is linked to the antibody, the conjugation efficiency between the antibody and the physiologically active substance is remarkably improved as compared to that of the conventional art, and thus, the drug may be firmly bound without impairing the specificity of the antibody, thereby making it possible to accelerate commercialization of the antibody conjugate.
    Type: Application
    Filed: June 21, 2023
    Publication date: January 18, 2024
    Applicant: NOVELTY NOBILITY INC.
    Inventors: Tae Hyeon YOO, Jisoo PARK, Yumi Lee
  • Publication number: 20240016948
    Abstract: The invention provides compositions comprising a single protein having one or more molecules of a pharmaceutical agent tightly bound therein. The compositions are useful to decrease the toxicity and/or to widen the therapeutic window of the pharmaceutical agent. The invention also provides methods for preparing such a composition.
    Type: Application
    Filed: March 30, 2023
    Publication date: January 18, 2024
    Applicant: Sunstate Biosciences, LLC
    Inventor: Changjun Yu
  • Publication number: 20240016949
    Abstract: An antibody-drug conjugate, and an intermediate thereof, a preparation method therefor, and an application thereof. Provided is an antibody-drug conjugate as represented by formula I. The compound has good targetability, has a good inhibitory effect on HER3-positive tumor cells, and has good druggability and high safety. The antibody-drug conjugate has an inhibitory effect on HER3, has an inhibitory effect on SK-BR-3 and SW620 cells, and also has a good inhibitory effect on at least one of 22Rv1, LNCaP, NCI-H820, OVCAR-8, and HCC827 cells.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 18, 2024
    Inventors: Qingsong GUO, Yijun SHEN, Tong YANG, Bin BAO, Bei GAO, Fang WU, Jun XU
  • Publication number: 20240016950
    Abstract: Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes (e.g., wherein each complex is of the exemplary formula shown below) comprising a phosphorodiamidate morpholino oligomer (e.g., useful for targeting DMD) covalently linked to an antibody (e.g., anti-TfR1 antibody). In some embodiments, the complexes are formulated with histidine (e.g., L-histidine) and sucrose at a specified pH (e.g., about 5.0 to 7.0). Also provided are uses of these formulations for treating a subject having a mutated DMD allele associated with Duchenne Muscular Dystrophy.
    Type: Application
    Filed: August 24, 2023
    Publication date: January 18, 2024
    Applicant: Dyne Therapeutics, Inc.
    Inventors: Timothy Weeden, Scott Hilderbrand, Sean Spring, Peiyi Shen, Cody A. Desjardins, Romesh R. Subramanian, Mohammed T. Qatanani, Brendan Quinn, John Najim
  • Publication number: 20240016951
    Abstract: The present disclosure provides compositions and methods for treating allograft vasculopathy, for treating Moyamoya Diseases (MMD) and Moyamoya Syndrome (MMS), for treating inhibiting or preventing unwanted intimal proliferation in a subject by administering an ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) agent or an ectonucleotide pyrophosphatase phosphodiesterase-3 (ENPP3).
    Type: Application
    Filed: December 30, 2022
    Publication date: January 18, 2024
    Inventors: Damon Banks, Catherine A. Nester, Edward Skolnik, Markus Walz, Frank Rutsch, Yvonne Nitschke
  • Publication number: 20240016952
    Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a DMPK allele comprising a disease-associated-repeat. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
    Type: Application
    Filed: July 9, 2021
    Publication date: January 18, 2024
    Applicant: Dyne Therapeutics, Inc.
    Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden, Cody A. Desjardins, Brendan Quinn, John Najim
  • Publication number: 20240016953
    Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is linked to a targeting Ligand Unit through a Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.
    Type: Application
    Filed: March 3, 2023
    Publication date: January 18, 2024
    Inventors: Christopher Scott Neumann, Kathleen Olivas
  • Publication number: 20240016954
    Abstract: A composition for improving the solubility of poorly soluble substances is provided. The composition for improving the solubility of poorly soluble substances includes 60-97% by weight of cyclodextrin and/or a derivative thereof, 0.5-4% by weight of at least one water-soluble polymer and 0.4-30% by weight of at least one water-soluble stabilizer, wherein the at least one water-soluble stabilizer includes caffeine, and wherein the poorly soluble substance is a tyrosine kinase inhibitor.
    Type: Application
    Filed: September 21, 2023
    Publication date: January 18, 2024
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Wen-Chia HUANG, Yen-Jen WANG, Felice CHENG, Chia-Ching CHEN, Shao-Chan YIN, Chien Lin PAN, Tsan-Lin HU, Meng-Nan LIN, Kuo-Kuei HUANG, Maggie LU, Chih-Peng LIU
  • Publication number: 20240016955
    Abstract: The present disclosure, at least in part, provides a dual-AAV vector system and compositions thereof for expression full-length PCDH15 in target cells. The present disclosure also provides the method of using the dual rAAV system for delivering full-length PCDH15 to a target cell (e.g., inner cells or cells in the eye) for treating deafness and/or blindness (e.g., Usher syndrome 1F).
    Type: Application
    Filed: September 14, 2021
    Publication date: January 18, 2024
    Applicant: President and Fellows of Harvard College
    Inventors: David P. Corey, Eric M. Mulhall, Maryna V. Ivanchenko
  • Publication number: 20240016956
    Abstract: The present disclosure relates to an improved method of treating a patient with a recombinant adeno-associated virus (rAAV) by adjunctively administering to the patient via systemic administration a composition comprising at least one antibody or antigen-binding fragments thereof that is capable of neutralizing the non-systemically administered rAAV. The present disclosure further provides kits for the combination therapy.
    Type: Application
    Filed: November 9, 2021
    Publication date: January 18, 2024
    Inventors: Roberto CALCEDO DEL HOYO, Luc H. VANDENBERGHE
  • Publication number: 20240016957
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fr receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Application
    Filed: July 25, 2023
    Publication date: January 18, 2024
    Applicant: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
    Inventor: Kerry S. Campbell
  • Publication number: 20240016958
    Abstract: A method and system for detecting and treating a clot are disclosed. The method of detecting composition of a clot in a vessel of a patient may include introducing a solution containing tagged tissue plasminogen activator (tPA) into a circulatory system of the patient, waiting a predetermined time for the tagged tPA to interact with the clot, scanning an area of the patient corresponding to the clot, and outputting a composition of the clot based on an intensity of a signal at the clot in the scan corresponding to the tagged tPA.
    Type: Application
    Filed: July 15, 2022
    Publication date: January 18, 2024
    Applicant: Neuravi Limited
    Inventors: Anushree DWIVEDI, Ray MCCARTHY, Sarah JOHNSON
  • Publication number: 20240016959
    Abstract: In certain aspects, the present disclosure relates to novel radiopharmaceutical ketone molecules, including acetoacetate (AcAc) and/or beta-hydroxybutyrate (BHB), and methods of using one or more radiopharmaceutical ketone molecules or radiopharmaceutical compositions as imaging agents or tracers in positron emission tomography (PET) or combination PET and magnetic resonance imaging (MRI), e.g., as ketone-PET tracers. The methods may be used in diagnostic imaging methodologies in Alzheimer's disease, cognitive impairment, and other conditions of altered cerebral metabolism.
    Type: Application
    Filed: November 17, 2021
    Publication date: January 18, 2024
    Applicant: Cerecin Inc.
    Inventors: Ernest Wong, Judith Walker, Samuel T. Henderson
  • Publication number: 20240016960
    Abstract: The present description relates to a conjugated compound an antibody covalently linked to enhancer moiety composed by a nuclear localization sequence (NLS), covalently linked to a sterol variant, such as cholic acid (ChAc) or a variant thereof. The enhancer moiety as encompassed herein is able to induce endosome escape of the compound-conjugates by direct membrane destabilization or indirectly by ROS and ceramide production which destabilize endosome-lysosome membrane. The conjugated compound can further comprise payload.
    Type: Application
    Filed: July 12, 2023
    Publication date: January 18, 2024
    Inventor: Simon BEAUDOIN
  • Publication number: 20240016961
    Abstract: Autoclave sterilisation facility for transfer bags is provided with a flexible container and with a rigid connection portion, the flexible container being connected to the rigid connection portion by a weld, the weld being contained in a plane, called the weld plane, substantially normal to the longitudinal axis of the connection portion, the facility including an autoclave sterilisation enclosure and a support including support plates configured to house in said enclosure, bags being intended to be disposed on the support plates, the rigid connection portion being oriented opposite the support plate and a retention tool disposed on the bag in such a way as to limit the mechanical stress of the weld.
    Type: Application
    Filed: October 29, 2021
    Publication date: January 18, 2024
    Inventors: Cyril MOUNIER, Anne-Claude GILBERT, Nicolas BOSCO
  • Publication number: 20240016962
    Abstract: A system for eradicating pathogens is disclosed. A lamp is provided that emits a far-ultraviolet C (far-UVC) light generates an irradiation zone. A biometric sensor determines whether an individual is present in the irradiation zone. The biometric sensor signals a processor to determine whether the individual has been exposed to a threshold limit of far-UVC light. The processor determines whether the time an individual has been in the irradiation zone exceeds a threshold limit. If the individual has been in the irradiation zone a period of time exceeds the threshold, the lamp is deactivated. A pathogen detection sensor provides user feedback of the existence pathogens and signals the processor to terminate irradiation or provide user feedback to terminate irradiation. The system and method are included in a passenger compartment of a vehicle to eradicate pathogens on surfaces and aerosol. Threshold limits allow eradication while the vehicle is occupied.
    Type: Application
    Filed: October 5, 2023
    Publication date: January 18, 2024
    Applicant: FREESTYLE PARTNERS LLC
    Inventors: JENNIFER K. ROSEN, BANJAMIN X. FEENEY, GREGORY D. DEGRAZIA
  • Publication number: 20240016963
    Abstract: A UV emission device includes an irradiator, a control unit, a determiner, and an exposure amount output unit. The irradiator irradiates a predetermined irradiation area in a predetermined space with ultraviolet rays. The control unit controls the irradiator based on a total exposure amount of a target person to ultraviolet rays. The determiner performs a determination process of determining whether or not the target person is present in the irradiation area. The exposure amount output unit outputs an amount of exposure of the target person to ultraviolet rays based on a determination result of the determiner and operation information on the irradiator. The control unit adds the amount of exposure of ultraviolet rays to the total exposure amount of ultraviolet rays in order to update the total exposure amount.
    Type: Application
    Filed: September 28, 2023
    Publication date: January 18, 2024
    Inventors: Tomoki SAITO, Toshio TANAKA, Kiyoshi KUROI, Mamoru OKUMOTO
  • Publication number: 20240016964
    Abstract: A dock for a floor cleaner. For example, a dock for receiving a floor cleaner, the dock including a receiving unit for receiving the floor cleaner, and a reservoir for containing a disinfecting liquid. The dock further includes an applicator arranged to apply the disinfecting liquid to at least part of a floor cleaner received in the receiving unit. The application of disinfecting liquid to at least part of the floor cleaner may improve the hygiene of the floor cleaner and maintain the floor cleaner in a useable state.
    Type: Application
    Filed: November 17, 2021
    Publication date: January 18, 2024
    Applicant: Dyson Technology Limited
    Inventor: Oliver DODGSON
  • Publication number: 20240016965
    Abstract: The present invention provides an ultraviolet-sensing member in which it is easy to determine whether an irradiation amount which inactivates the novel coronavirus has been irradiated, and an ultraviolet-sensing kit. The ultraviolet-sensing member of the present invention contains a sensitizer having an absorption maximal wavelength in a range of 200 to 230 nm, a photoactivator, and a color-forming agent.
    Type: Application
    Filed: September 22, 2023
    Publication date: January 18, 2024
    Applicant: FUJIFILM Corporation
    Inventor: Nobutaka FUKAGAWA
  • Publication number: 20240016966
    Abstract: The present invention relates to freshening compositions, devices comprising same and methods of using and manufacturing same. A freshening composition of this invention may comprise (i) from about 0.1 wt % to about 95 wt % perfume raw material, (ii) from about 0.01 wt % to about 90 wt % fragrance release modulator, and (iii) from about 1.0 wt % to about 95 wt % solvent. Some freshening composition further comprise an ingredient having a functional activity. Disclosed are passive and active air or surface freshening products comprising a freshening composition that allow controlled and customized release of the freshening composition or of a component thereof into or onto an environment. The addition of a fragrance release modulator to formulate a freshening composition of the present invention allows the modulation of the release of the freshening composition or of a component thereof.
    Type: Application
    Filed: September 21, 2023
    Publication date: January 18, 2024
    Inventors: Florin-Iosif VLAD, Austin HOWARD
  • Publication number: 20240016967
    Abstract: A germicidal device that includes a lamp cap, a grating component, a lamp body, a germicidal component and a fan component, where the grating component is provided with a central hole and several baffles which are provided at intervals to form several light outlets; the germicidal component is provided in the central hole for emitting UV light part of which is emitted via the light outlets; the bottom of the lamp body is provided with the first ventilation hole which connects to the central hole; the fan component is provided corresponding to the first ventilation hole for ventilation of the germicidal device.
    Type: Application
    Filed: May 13, 2021
    Publication date: January 18, 2024
    Applicant: SHENZHEN GUANKE TECHNOLGIES CO., LTD
    Inventors: Qing LAN, Shoubao CHEN, Ligen LIU
  • Publication number: 20240016968
    Abstract: An ozone purification device is disclosed. The ozone purification device comprises an ultraviolet light source and a filter. The ultraviolet light source includes an ultraviolet lamp and a LED lamp. The ultraviolet lamp generates ultraviolet rays and the LED lamp generates heat. The filter is composed of a metal composite catalyst coated with an active carbon. When ozone passes through the ultraviolet light source, ozone is irradiated by the ultraviolet light lamp and the LED lamp of the ultraviolet light source, and then passes through the metal composite catalyst and the active carbon of the filter to accelerate the decomposition of ozone into oxygen.
    Type: Application
    Filed: April 13, 2023
    Publication date: January 18, 2024
    Applicant: Microjet Technology Co., Ltd.
    Inventors: Hao-Jan Mou, Chin-Chuan Wu, Yung-Lung Han, Chi-Feng Huang
  • Publication number: 20240016969
    Abstract: An air conditioner indoor unit includes a power supply device, a control device, a negative electrode discharge device, and a positive electrode discharge device. The negative electrode discharge device is configured to ionize air to generate air negative ions. The positive electrode discharge device is configured to ionize air to generate air positive ions. The control device is configured to determine an operation mode of the air conditioner indoor unit according to first information, control the power supply device to supply power to the negative electrode discharge device and the positive electrode discharge device in a case where the operation mode is a first purification mode, and control the power supply device to supply power to the negative electrode discharge device and stop supplying power to the positive electrode discharge device in a case where the operation mode is a second purification mode.
    Type: Application
    Filed: July 19, 2023
    Publication date: January 18, 2024
    Applicant: HISENSE AIR CONDITIONING CO., LTD.
    Inventors: Bo WEN, Yunxi LI, Lingqing MA, Fengjiao ZHANG, Xinyu ZHANG
  • Publication number: 20240016970
    Abstract: Provided are peptides that are derived from probiotic bacteria that may be useful for preventing and/or treating enteric infections or non-enteric infections in a subject. The peptides may also find use for reducing the virulence of enteric infections or non-enteric infections in a subject. Also provided are compositions of the peptides and compositions comprising culture fractions of the probiotic bacteria.
    Type: Application
    Filed: June 2, 2023
    Publication date: January 18, 2024
    Inventors: Monica Angela Cella, Sarah M. Curtis, Jonathon Patrick Roepke
  • Publication number: 20240016971
    Abstract: A phenol derivative-modified, tissue-derived extracellular matrix derivative for construction of artificial tissues. A hydrogel composition and a hydrogel prepared therefrom exhibit various effects such as hemostasis, blood coagulation acceleration, cell transplantation, drug delivery, cell differentiation promotion, etc. and thus can be applied to single or composite uses. Furthermore, the present invention is excellent in biocompatibility due to its biodegradability and being almost free of cytotoxicity, thus exhibiting very high applicability. In addition, a tissue structure including a single type or multiple types of cells can be formed through the cell-proliferating potential and adhesion of the hydrogel and can better simulate in-vivo microenvironments.
    Type: Application
    Filed: September 27, 2023
    Publication date: January 18, 2024
    Inventors: Seung Woo CHO, Soo Hwan AN, Su Kyeom KIM, Yu Heun KIM, Su Ran KIM, Sung Jin MIN, Se Won PARK
  • Publication number: 20240016972
    Abstract: Described herein are tough gel compositions that comprise an interpenetrating networks (IPN) hydrogel. The IPN hydrogel comprises a first polymer network (covalently crosslinked) and a second polymer network (ionically crosslinked), at least one therapeutic agent, and a clay material. The tough gel compositions may further include an adhesive polymer layer attached to the IPN hydrogel. Methods of use of these compositions, such as for extended release drug delivery, are also described.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 18, 2024
    Inventors: Benjamin Ross Freedman, David J. Mooney